Friday, 16 October 2026European Markets

REINET INVESTMENTS Stock 9.57% Up Before The Weekend

Loading stream...

(VIANEWS) - The Market ended the session with REINET INVESTMENTS (REINA.AS) jumping 9.57% to €20.60 on Friday, following the last session's downward trend. AEX-Index jumped 0.04% to €736.31, after three successive sessions in a row of gains, on what was a somewhat positive trend trading session today.

About REINET INVESTMENTS

Reinet Investments S.C.A. operates as a securitization vehicle in Luxembourg. The company, through its subsidiary, Reinet Fund S.C.A., F.I.S., invests in assets. Reinet Investments Manager S.A. operates as a general partner of Reinet Investments S.C.A. The company was formerly known as Richemont S.A. and changed its name to Reinet Investments S.C.A. in October 2008. Reinet Investments S.C.A. was incorporated in 1979 and is based in Luxembourg City, Luxembourg.

Earnings Per Share

As for profitability, REINET INVESTMENTS has a trailing twelve months EPS of €-0.66.

Volatility

REINET INVESTMENTS's last week, last month's, and last quarter's current intraday variation average was a positive 0.35%, a negative 0.56%, and a positive 3.55%.

REINET INVESTMENTS's highest amplitude of average volatility was 4.60% (last week), 4.28% (last month), and 3.55% (last quarter).

Volume

Today's last reported volume for REINET INVESTMENTS is 1403 which is 510% above its average volume of 230.

More news about REINET INVESTMENTS (REINA.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com